Novartis’s Kisqali Approved by EC for Adjuvant Treatment of High-Risk Early Breast Cancer
Swiss pharmaceutical company Novartis (NYSE: NVS) has announced that it has received marketing approval from...
Sanofi Launches Modulus, a Pioneering Manufacturing Facility in Singapore
Global healthcare company Sanofi (NASDAQ: SNY) has inaugurated Modulus, its state-of-the-art manufacturing facility in Singapore....
Chia Tai Tianqing’s Benmelstobart Combo Approved by NMPA for Endometrial Cancer Treatment
China-based Chia Tai Tianqing has announced that the National Medical Products Administration (NMPA) has granted...
Sichuan Kelun-Biotech’s SKB264/MK-2870 Approved by NMPA for Triple Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a China-based biopharmaceutical company, has received market approval...
NHC Aims for Nationwide Inspection Result Sharing in Medical Consortia by 2030
The National Healthcare Commission (NHC) has issued the “Guiding Opinions on Further Promoting Mutual Recognition...
CORXEL’s Varenicline Nasal Spray Approved by NMPA for Dry Eye Treatment
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has received approval...
Arrowhead and Sarepta Seal $11.38 Billion Global Licensing Deal for Rare Disease Treatments
US-based companies Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) and Sarepta Therapeutics (NASDAQ: SRPT) have announced a...
Pfizer Partners with CR Pharma to Expand Cancer Drug Access in China
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has entered into a strategic agreement with China...
Roche’s Evrysdi Receives Patent Term Extension in China, Extending Protection to 2035
The China National Intellectual Property Administration (CNIPA) has granted Swiss pharmaceutical giant Roche (SWX: ROG)...
CanSino Biologics’ Menhycia Vaccine Aims to Expand Age Range with NMPA Filing
CanSino Biologics (HKG: 6185) has announced that the National Medical Products Administration (NMPA) has accepted...
Jiangsu Hengrui Medicine’s SHR-1819 Receives NMPA Approval for Atopic Dermatitis Clinical Trial
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received clinical trial...
AstraZeneca’s Truqap Meets Primary Endpoint in Phase III Prostate Cancer Study
UK-based pharmaceutical giant AstraZeneca Inc., (AZ, NASDAQ: AZN) has announced that its Phase III CAPItello-281...
Sichuan Huiyu Pharmaceutical’s HY-2003 Approved for Clinical Trials by China’s NMPA
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...
J&J’s Stelara Faces New Biosimilar Competition in China with CSPC Pharmaceutical’s Entry
Johnson & Johnson (J&J, NYSE: JNJ)’s auto-immune disease drug Stelara (ustekinumab) is set to encounter...
AstraZeneca’s ALXN1850 (Efzimfotase Alfa) Selected for China’s Rare Disease Care Plan
The Center for Drug Evaluation (CDE) in China has announced its intention to include AstraZeneca’s...
Amgen’s MariTide Showcases Significant Weight Loss in Phase II Study
US biotechnology company Amgen (NASDAQ: AMGN) has announced positive outcomes from the double-blind, dose-ranging Phase...
VectorBuilder and Zhejiang Dapu Biotechnology Form Partnership to Advance Biotech Innovation
China-based gene delivery technology developer VectorBuilder has entered into a partnership with Zhejiang Dapu Biotechnology...
Roche’s SKYSCRAPER-01 Study: Tiragolumab-Tecentriq Combo Misses Primary Endpoint in NSCLC
Swiss pharmaceutical giant Roche (SWX: ROG) has reported an update on the phase III SKYSCRAPER-01...
Roche to Acquire Poseida Therapeutics in a USD 1.5 Billion Deal
US-based clinical-stage biopharmaceutical company, Poseida Therapeutics (NASDAQ: PSTX), which specializes in donor-derived CAR-T cell therapies,...
Zymeworks and Jazz Pharmaceuticals’ Ziihera Gets Green Light for HER2+ BTC Treatment
Partners Zymeworks Inc. (NASDAQ: ZYME) and Jazz Pharmaceuticals, Inc. have received accelerated approval from the...